UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Akt-Dependent Metabolic Reprogramming Regulates Tumor Cell Histone Acetylation

Cell metabolism, 2014-08, Vol.20 (2), p.306-319

2014

Volltextzugriff (PDF)

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma

European urology, 2017-10, Vol.72 (4), p.557-564

2017

Volltextzugriff (PDF)

Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis

European urology, 2018-11, Vol.74 (5), p.611-620

2018

Volltextzugriff (PDF)

Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial

Nature communications, 2024-03, Vol.15 (1), p.2570-2570, Article 2570

2024

Volltextzugriff (PDF)

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study

Journal of clinical oncology, 2014-10, Vol.32 (30), p.3391-3399

2014

Volltextzugriff (PDF)

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805

Clinical cancer research, 2018-01, Vol.24 (1), p.217-223

2018

Volltextzugriff (PDF)

Disease‐free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results‐Medicare datac

International journal of urology, 2023-03, Vol.30 (3), p.272-279

2023

Volltextzugriff (PDF)

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

Clinical cancer research, 2009-11, Vol.15 (22), p.7036-7044

2009

Volltextzugriff (PDF)

Real‐world study on the characteristics, post‐nephrectomy journey, and outcomes of patients with early‐stage renal cell carcinoma based on risk groups

Cancer medicine (Malden, MA), 2024-06, Vol.13 (11), p.e7247-n/a

2024

Volltextzugriff (PDF)

Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

International journal of radiation oncology, biology, physics, 2017-02, Vol.97 (2), p.355-361

2017

Volltextzugriff (PDF)

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Future oncology (London, England), 2019-05, Vol.15 (15), p.1683-1695

2019

Volltextzugriff (PDF)

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Journal for immunotherapy of cancer, 2024-04, Vol.12 (4), p.e008293

2024

Volltextzugriff (PDF)

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

The New England journal of medicine, 2021-08, Vol.385 (8), p.683-694

2021

Volltextzugriff (PDF)

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

Journal for immunotherapy of cancer, 2023-03, Vol.11 (3), p.e004780

2023

Volltextzugriff (PDF)

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

Cancer medicine (Malden, MA), 2021-09, Vol.10 (17), p.5917-5924

2021

Volltextzugriff (PDF)

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

Journal of clinical oncology, 2017-12, Vol.35 (35), p.3916-3923

2017

Volltextzugriff (PDF)

Nivolumab Plus Ipilimumab with Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma

Journal of vascular and interventional radiology, 2023-06, Vol.34 (6), p.1089-1091.e1

2023

Volltextzugriff (PDF)

Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma

Clinical cancer research, 2019-04, Vol.25 (7), p.2080-2087

2019

Volltextzugriff (PDF)

Hereditary Kidney Cancer Syndromes

Advances in chronic kidney disease, 2014, Vol.21 (1), p.81-90

2014

Volltextzugriff (PDF)

Surveillance for Renal Cell Cancer Recurrence: Which Patients Should Undergo Imaging, How Often, and When?

Journal of clinical oncology, 2015-12, Vol.33 (35), p.4131-4133

Haas, Naomi B

2015

Volltextzugriff (PDF)

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation

Journal of clinical oncology, 2019-08, Vol.37 (23), p.2062-2071

2019

Volltextzugriff (PDF)

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

Journal of clinical oncology, 2022-09, Vol.40 (25), p.2913-2923

2022

Volltextzugriff (PDF)

Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future

The oncologist (Dayton, Ohio), 2014-08, Vol.19 (8), p.851-859

2014

Volltextzugriff (PDF)

1 – 25 von 212

Suche als RSS-Feed

Aktive Filter

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(209)
Mit Volltextzugriff
(183)

Publikationsform

Artikel
(212)

Sprache

Englisch
(212)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Life Sciences & Biomedicine
(84)
Humans
(72)
Oncology
(58)
Male
(39)
Carcinoma, Renal Cell - Drug Therapy
(31)
Female
(30)
Middle Aged
(29)
Aged
(28)
Kidney Neoplasms - Drug Therapy
(25)
Kidney Cancer
(24)
Kidney Neoplasms - Pathology
(24)
Carcinoma, Renal Cell - Pathology
(23)
Renal Cell Carcinoma
(23)
Adult
(20)
Disease-Free Survival
(20)
Patients
(20)
Urology & Nephrology
(20)
Nephrectomy
(18)
Treatment Outcome
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Akt-Dependent Metabolic Reprogramming Regulates Tumor Cell Histone Acetylation

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma

Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis

Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805

Disease‐free survival as a predictor of overall survival in localized renal cell carcinoma following initial nephrectomy: A retrospective analysis of Surveillance, Epidemiology and End Results‐Medicare datac

Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

Real‐world study on the characteristics, post‐nephrectomy journey, and outcomes of patients with early‐stage renal cell carcinoma based on risk groups

Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

Nivolumab Plus Ipilimumab with Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma

Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma

Hereditary Kidney Cancer Syndromes

Surveillance for Renal Cell Cancer Recurrence: Which Patients Should Undergo Imaging, How Often, and When?

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future

Aktive Filter

Suchergebnisse filtern